Enlivex Rallies On Encouraging Allocetra Data In Mid-Stage COVID-19 Study

  • Enlivex Therapeutics Ltd (NASDAQ: ENLV) stock rises sharply on the heels of positive data from the Phase 2 trial evaluating Allocetra in severe and critical COVID-19 patients. 
  • Data showed that out of 16 patients treated, 14 patients (87.5%) recovered and were discharged from the hospital by day-28. Zero mortality rate was observed on day-28.
  • The average duration of hospitalization post administration of Allocetra for discharged patients was 5.3 days.
  • 2/16 (12.5%) patients, both of whom had a critical illness at the time of Allocetra treatment, were hospitalized in the ICU on a respirator on day-28.
  • Based on the results and in consultation with the trial's principal investigator, the Company has completed the trial early. It plans to submit a summary of the data for review by the relevant regulatory bodies later this month.
  • Allocetra is a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state.
  • Price Action: ENLV shares are trading higher by 11.4% at $14.54 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsGeneralCovid-19
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!